The Supreme Court ruled 7-2 on June 25 that federal pesticide law bars state failure-to-warn suits over Roundup, handing Bayer the legal shield it spent a decade chasing. Monsanto says the decision should dismiss claims now pending and largely end the litigation that has dogged its glyphosate franchise. The ruling strips out one of the last accountability levers sitting outside the market, and consumer capital has already concluded that the market is now the referee.
That conclusion shows up in where money is moving. Venture and growth investors spent 2025 and early 2026 repricing clean as a durable category rather than a wellness fad, helped by an unusual regulatory tailwind. The Trump administration’s Make America Healthy Again (MAHA) campaign has pushed roughly a third of the US food industry to drop artificial dyes, turning reformulation into a procurement problem with a startup-shaped answer. Innova Market Insights found that 23% of new product launches carry at least one MAHA-targeted ingredient, with large manufacturers exposed at nearly twice the rate of independents. Every one of those products is a reformulation contract waiting to be signed. Capital is also more selective than in the last cycle, consolidating into larger rounds with hard scrutiny on unit economics, which rewards proof over narrative.
The market map
Brand rounds map the demand. David, a high-protein bar maker, raised a $75 million Series A in 2025 and acquired its plant-based fat supplier to lock down a scarce ingredient. India’s The Whole Truth, built on radical ingredient transparency, closed about $51 million in a Series D this year. Mosh, positioned around brain health, took in roughly $13 million in May, and VMG Partners bought a growth stake in collagen-bar brand Stars and Honey. The shared bet is that a label a shopper can read without a chemistry degree now commands a premium.
The more investable layer sits upstream. Reformulation is hard, and the firms selling the inputs capture margin from every brand forced to comply. Fermentation-derived ingredients are drawing checks and CPG partnerships as a route to replace eggs, dyes, sweeteners and fats without synthetic additives. Every, which makes an animal-free egg protein, says 2026 orders already run at 550% of last year’s volume. Sweet-protein and prebiotic-fiber startups are selling sugar reduction, the single largest unmet demand in the aisle. For investors burned by the plant-based meat cycle, B2B ingredients carry the same thesis with stickier contracts and less brand risk.
The map runs past the grocery shelf; regenerative agriculture has hardened into a financeable asset class, with funds such as Mad Capital raising $50 million to underwrite regenerative farmland transitions, and roughly 250 food and land use startups raised capital in 2024, a volume second only to energy across climate tech. Personal care offers the cleanest read on the same consumer. Grand View Research values the clean beauty market at $10.49 billion in 2025 and projects $35.30 billion by 2033, a 16.8% compound rate that outpaces conventional cosmetics. High repeat rates and label scrutiny give the category venture upside with consumer-staples economics.
The countercurrent
The other direction deserves equal weight. Big Food is retreating from the disclosure it once advertised. As You Sow’s 2026 Pesticides in the Pantry scorecard found 10 of 17 major food companies scored lower than in 2023, with General Mills, ADM and Conagra walking back pesticide commitments. General Mills also 301 Inc paused new investments through its venture arm in 2025, a sign that incumbents would rather buy proven challengers than seed them. MAHA’s scientific credibility is contested by some, and often described as a movement blending real concern over ultra-processed food with anti-vaccine messaging. Clean still has no shared legal definition, which leaves every claim exposed to the same labeling risk the Court just narrowed for pesticides.
Durnell confirms that federal regulators, not courts or states, will set the floor for what companies must disclose, and that floor is dropping. Demand for products that opt out of the uncertainty is structural, and the capital is flowing to the suppliers, brands and farmland that let consumers self-regulate. For founders, the differentiator has moved from story to proof. Third-party testing, biomarker data and supply traceability are what hold up when the label is the only thing a buyer can trust. The companies that can verify their claims will own the category regulators are vacating.
